2026 #NLASessions Satellite Symposia
Satellite Symposia are industry-supported, non-CME programs held outside the core scientific agenda, typically in early morning or evening timeframes. These sessions are designed for deeper exploration of cutting-edge research, clinical insights, and evolving therapeutic strategies in lipidology and cardiovascular risk reduction.
Featuring expert faculty and extended presentation time, Satellite Symposia provide a more comprehensive, lecture-style experience—often paired with a hosted meal or reception. All registered attendees are welcome to participate.
Thursday, June 11
June 11, 2026 | 4:00 – 6:00 pm
This continuing education activity is provided by the National Lipid Association.
Educational Partner: Vindico Medical Education
Kick off your weekend in Chicago with this Opening Session CE Symposium! This live, case-based activity will review key recommendations for primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD). Through real-world clinical scenarios, expert faculty will share practical strategies for applying the updated guidelines—including improved risk assessment, established target thresholds for treatment, and earlier intervention.
This is an independent satellite CME/CE symposium held in conjunction with the NLA 2026 Scientific Sessions. It is not part of the official sessions as planned by the NLA Scientific Meetings Committee.
This activity is supported by educational funding provided by Amgen; Esperion Therapeutics, Inc.; Merck & Co., Inc.; and Novartis Pharmaceuticals Corporation.
Applying New Guidelines to Address the Challenge of Lipid Management
June 11, 2026 | 7:15 – 8:15 pm
This continuing education activity is provided by the National Lipid Association.
Educational Partner: PVI, PeerView Institute for Medical Education.
Key Reasons to Attend
- Learn strategies to overcome barriers to optimal lipid management in those at high risk of ASCVD
- Enhance your understanding of how guidelines recommend using combination therapies to meet LDL-C goals
- Improve your ability to partner with patients and improve adherence using shared decision-making and team-based care
This is an independent satellite CME/CE symposium held in conjunction with the NLA 2026 Scientific Sessions. It is not part of the official sessions as planned by the NLA Scientific Meetings Committee.
This activity is supported by an educational grant from Merck & Co., Inc.Rahway, NJ
Friday, June 12
Friday, June 12, 2026 | 6:45 - 8:45 am
This continuing education activity is provided by the National Lipid Association.
Educational Partner: Vindico Medical Education
Many patients with dyslipidemia, particularly those at high cardiovascular (CV) risk, do not achieve recommended low-density lipoprotein cholesterol (LDL-C) targets, resulting in persistent residual risk. Updated guidelines highlight the need for more intensive and individualized lipid-lowering strategies, yet gaps remain in clinician knowledge regarding newer therapeutic approaches. Cholesteryl ester transfer protein (CETP) inhibition has re-emerged as a promising mechanism, with recent clinical data demonstrating reductions in LDL-C, apolipoprotein B (apoB), and lipoprotein(a) (Lp[a]) with a promising safety profile in high-risk populations. Additionally, emerging evidence suggests a potential link between lipid lowering and reduced neurocognitive risk. This live, case-based CME activity will review the latest evidence on CETP inhibition and engage learners through a unique CME Situation Room component to apply these data to clinical practice to optimize dyslipidemia management and improve patient outcomes.
This is an independent satellite CME/CE symposium held in conjunction with the NLA 2026 Scientific Sessions. It is not part of the official sessions as planned by the NLA Scientific Meetings Committee.
This activity is supported by an educational grant from NewAmsterdam Pharma B.V.